Efficacy News and Research

RSS
MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial

MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial

Delcath Systems to initiate Expanded Access Program for melphalan in patients with metastatic melanoma to the liver

Delcath Systems to initiate Expanded Access Program for melphalan in patients with metastatic melanoma to the liver

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

NorTech announces winners of annual Innovation Awards program

NorTech announces winners of annual Innovation Awards program

Genous Bio-engineered R stent beneficial for patients not suitable for long term DAPT

Genous Bio-engineered R stent beneficial for patients not suitable for long term DAPT

CoAxia completes enrollment in NeuroFlo Perfusion Augmentation Therapy trial for ischemic stroke

CoAxia completes enrollment in NeuroFlo Perfusion Augmentation Therapy trial for ischemic stroke

Ragweed pollen allergy: SLIT safe and effective alternative to injections

Ragweed pollen allergy: SLIT safe and effective alternative to injections

Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study

Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study

Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis

Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis

Data demonstrates the effectiveness of NeuroAiD on neuronal and brain injuries

Data demonstrates the effectiveness of NeuroAiD on neuronal and brain injuries

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Third party reexamination of Phase III study of Ereska meets primary endpoint

Third party reexamination of Phase III study of Ereska meets primary endpoint

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Sustamine L-Alanyl-L-Glutamine supplement increases performance in endurance exercise and activity

Sustamine L-Alanyl-L-Glutamine supplement increases performance in endurance exercise and activity

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

Ulcerative colitis drug market to grow up to $2.1 billion in 2018

Ulcerative colitis drug market to grow up to $2.1 billion in 2018

Second-quarter fiscal 2010 results announced by Pharmacyclics

Second-quarter fiscal 2010 results announced by Pharmacyclics

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.